AR008392A1 - Procedimiento que utiliza una porfirina verde para preparar un medicamento para prevenir o inhibir la formacion de placas arteriales y la composicionfarmaceutca obtenida por dicho procedimiento - Google Patents

Procedimiento que utiliza una porfirina verde para preparar un medicamento para prevenir o inhibir la formacion de placas arteriales y la composicionfarmaceutca obtenida por dicho procedimiento

Info

Publication number
AR008392A1
AR008392A1 ARP970102602A ARP970102602A AR008392A1 AR 008392 A1 AR008392 A1 AR 008392A1 AR P970102602 A ARP970102602 A AR P970102602A AR P970102602 A ARP970102602 A AR P970102602A AR 008392 A1 AR008392 A1 AR 008392A1
Authority
AR
Argentina
Prior art keywords
procedure
prevent
green porphyrin
prepare
pharmaceutical composition
Prior art date
Application number
ARP970102602A
Other languages
English (en)
Original Assignee
Qlt Phototherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qlt Phototherapeutics Inc filed Critical Qlt Phototherapeutics Inc
Publication of AR008392A1 publication Critical patent/AR008392A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Un procedimiento que utiliza una porfirina verde para preparar un medicamento para prevenir o inhibir la formacion de placas arteriales queconsiste en a) administrar dicho medicamento a un sujeto que necesita dicha prevencion oinhibici on y b) permitir que dicha prevencion o inhibicion seproduzca en ausencia de irradiacion de una luz absorbida por la porfiria verde. Se refiere también a una composicion farmacéutica para prevenir o inhibir laformacion de placas arteriales.La compos icion comprende: a) una cantidad de un compuesto de porfirina verde efectiva para prevenir o inhibir la formacion deplacas arteriales cuando se la administra a un individuo que necesita dicho tratamiento, incluso en ausencia deirradiacion de un a luz absorbida por dichaporfirina verde y b) un excipiente aceptable en términos farmacéuticos. No es necesario que la administracion de la porfirina verde está acompanada por lairradiacion intencional de luz.
ARP970102602A 1996-06-14 1997-06-13 Procedimiento que utiliza una porfirina verde para preparar un medicamento para prevenir o inhibir la formacion de placas arteriales y la composicionfarmaceutca obtenida por dicho procedimiento AR008392A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/663,890 US5834503A (en) 1996-06-14 1996-06-14 Methods to treat arterial plaque

Publications (1)

Publication Number Publication Date
AR008392A1 true AR008392A1 (es) 2000-01-19

Family

ID=24663656

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970102602A AR008392A1 (es) 1996-06-14 1997-06-13 Procedimiento que utiliza una porfirina verde para preparar un medicamento para prevenir o inhibir la formacion de placas arteriales y la composicionfarmaceutca obtenida por dicho procedimiento

Country Status (13)

Country Link
US (2) US5834503A (es)
EP (1) EP0910371A1 (es)
JP (1) JP2000512300A (es)
KR (1) KR20000016656A (es)
CN (1) CN1101188C (es)
AR (1) AR008392A1 (es)
AU (1) AU714045B2 (es)
CA (1) CA2257564A1 (es)
HU (1) HUP0001063A3 (es)
NO (1) NO985829L (es)
NZ (1) NZ333236A (es)
TW (1) TW514527B (es)
WO (1) WO1997048393A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834503A (en) * 1996-06-14 1998-11-10 Qlt Phototherapeutics, Inc. Methods to treat arterial plaque
DE19824653A1 (de) * 1998-02-25 1999-08-26 Schering Ag Nekrose-affine Verbindungen und ihre Verwendung zur Herstellung von Präparaten zur Pharmakotherapie
US6331235B1 (en) * 1998-12-11 2001-12-18 The University Of British Columbia Chiral separation of benzoporphyrin derivative mono-and di-acids by laser-induced fluorescence capillary electrophoresis
US6609014B1 (en) * 1999-04-14 2003-08-19 Qlt Inc. Use of PDT to inhibit intimal hyperplasia
US7022843B1 (en) 1999-04-14 2006-04-04 The University Of British Columbia β,β′-dihydroxy meso-substituted chlorins, isobacteriochlorins, and bacteriochlorins
US20040229295A1 (en) * 1999-05-17 2004-11-18 Marchitto Kevin S. Activated delivery of biomolecules using electromagnetic energy
US20040208855A1 (en) * 1999-11-17 2004-10-21 Allison Beth Anne Use of PDT to inhibit intimal hyperplasia
US6750037B2 (en) * 1999-12-27 2004-06-15 Edwin L. Adair Method of cancer screening primarily utilizing non-invasive cell collection, fluorescence detection techniques, and radio tracing detection techniques
US6984498B2 (en) * 1999-12-27 2006-01-10 Adair Edwin L Method of cancer screening primarily utilizing non-invasive cell collection, fluorescence detection techniques, and radio tracing detection techniques
WO2002064163A2 (en) 2001-02-15 2002-08-22 Qlt Inc. Reduction or prevention of pdt related inflammation
US6790463B2 (en) * 2001-03-30 2004-09-14 Robert F. Hofmann Uses of targeted oxidative therapeutic formulation in arteriosclerosis
US20030103995A1 (en) 2001-06-04 2003-06-05 Hamblin Michael R. Detection and therapy of vulnerable plaque with photodynamic compounds
ATE336266T1 (de) * 2002-06-21 2006-09-15 Adair Edwin Lloyd Anwendung von metalloporphyrinen zur behandlung von arteriosklerose
US20080193376A1 (en) * 2004-10-28 2008-08-14 The General Hospital Corporation Methods of Enhanced Detection and Therapy of Inflamed Tissues Using Immune Modulation
US20080260650A1 (en) * 2004-10-28 2008-10-23 The General Hospital Corporation Methods of Detection and Therapy of Inflamed Tissues Using Immune Modulation
US8109981B2 (en) 2005-01-25 2012-02-07 Valam Corporation Optical therapies and devices
US7465312B2 (en) 2006-05-02 2008-12-16 Green Medical, Inc. Systems and methods for treating superficial venous malformations like spider veins
US20070299431A1 (en) * 2006-05-02 2007-12-27 Green Medical, Inc. Systems and methods for treating superficial venous malformations like spider veins
US7968127B2 (en) * 2008-07-28 2011-06-28 Winslow David E Reverse vitamin K effect via photodynamic oxidation targeted at vascular endothelium, fibrin and blood platelets
CN102743330B (zh) 2008-07-28 2016-03-23 武田药品工业株式会社 药物组合物
CN115054703B (zh) * 2022-06-30 2023-08-04 东南大学 具有近红外光响应性和靶向性的脂质体、制备方法及应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4512762A (en) * 1982-11-23 1985-04-23 The Beth Israel Hospital Association Method of treatment of atherosclerosis and a balloon catheter for same
US4577636A (en) * 1982-11-23 1986-03-25 The Beth Israel Hospital Association Method for diagnosis of atherosclerosis
US5283255A (en) * 1987-01-20 1994-02-01 The University Of British Columbia Wavelength-specific cytotoxic agents
US5171749A (en) * 1987-01-20 1992-12-15 University Of British Columbia Wavelength-specific cytotoxic agents
US4920143A (en) * 1987-04-23 1990-04-24 University Of British Columbia Hydro-monobenzoporphyrin wavelength-specific cytotoxic agents
US5095030A (en) * 1987-01-20 1992-03-10 University Of British Columbia Wavelength-specific cytotoxic agents
US5150717A (en) * 1988-11-10 1992-09-29 Arye Rosen Microwave aided balloon angioplasty with guide filament
US5214036A (en) 1990-03-08 1993-05-25 University Of British Columbia Benzoporphyrin derivatives for photodynamic therapy
US5053423A (en) * 1990-03-22 1991-10-01 Quadra Logic Technologies Inc. Compositions for photodynamic therapy
EP0650368A1 (en) * 1992-06-24 1995-05-03 Cortex Pharmaceuticals, Inc. Use of calpain inhibitors in the inhibition and treatment of medical conditions associated with increased calpain activity
US5422362A (en) * 1993-07-29 1995-06-06 Quadra Logic Technologies, Inc. Method to inhibit restenosis
WO1995003795A1 (en) * 1993-07-29 1995-02-09 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Method of treating atherosclerosis or restenosis using microtubule stabilizing agent
US5789433A (en) * 1995-01-17 1998-08-04 Quadra Logic Technologies, Inc. Green porphyrins as immunomodulators
US5834503A (en) * 1996-06-14 1998-11-10 Qlt Phototherapeutics, Inc. Methods to treat arterial plaque

Also Published As

Publication number Publication date
NO985829L (no) 1999-02-11
AU714045B2 (en) 1999-12-16
TW514527B (en) 2002-12-21
US6235767B1 (en) 2001-05-22
US5834503A (en) 1998-11-10
HUP0001063A2 (hu) 2000-09-28
CN1222076A (zh) 1999-07-07
AU2947097A (en) 1998-01-07
NZ333236A (en) 2000-06-23
KR20000016656A (ko) 2000-03-25
WO1997048393A1 (en) 1997-12-24
HUP0001063A3 (en) 2001-02-28
NO985829D0 (es) 1998-12-11
CA2257564A1 (en) 1997-12-24
JP2000512300A (ja) 2000-09-19
EP0910371A1 (en) 1999-04-28
CN1101188C (zh) 2003-02-12

Similar Documents

Publication Publication Date Title
AR008392A1 (es) Procedimiento que utiliza una porfirina verde para preparar un medicamento para prevenir o inhibir la formacion de placas arteriales y la composicionfarmaceutca obtenida por dicho procedimiento
PT100635A (pt) Forma de dosagem farmaceutica para a administracao retardada de um farmaco
IL148127A (en) Use of ramipril or its pharmaceutical salt to prepare or prevent heart events in high-risk patients without evidence of left ventricular dysfunction
CY1111088T1 (el) Θεραπευτικη φαρμακοτεχνικη μορφη για χορηγηση τολτεροδινης με ελεγχομενη απελευθερωση
CA2240329A1 (en) Improved delivery of multiple doses of medications
BR0013540A (pt) Formulações farmacêuticas e seu uso na prevenção de acidente vascular cerebral, diabetes e/ou falha de coração congestiva
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
CA2301017A1 (en) Use of propyl gallate to increase bioavailability of orally administered pharmaceutical compounds
CZ309247B6 (cs) 40-O-(2-hydroxyethyl)rapamycin pro použití jako jediná účinná látka při léčení solidního nádoru
WO1995030423A3 (en) Cancer treatment and metastasis prevention
RU2008103617A (ru) Бисфосфоновые кислоты, предназначенные для лечения и профилактики остеопороза
AR020803A1 (es) Una composicion que comprende fexofenadina o una sal farmaceuticamente aceptable de la misma y el uso de la misma para la manufactura de unmedicamento
BR9708706B1 (pt) composiÇço farmacÊutica para administraÇço intravenosa a um paciente
IL300151A (en) Combinations for cancer treatment
AR035946A1 (es) Composiciones farmaceuticas estrogenicas para usar en el tratamiento de desordenes en mujeres perimenopausicas, menopausicas o posmenopausicas, y usos de dichas composiciones para la preparacion de medicamentos
EP1304108A3 (en) Anti-arrhythmic composition and methods of treatment
ES2121103T3 (es) Antagonistas de la angiotensina ii para el tratamiento de enfermedades viricas.
SV2002000036A (es) Inhibidores de acido abierto y sales de dihidroxilo de reductasa hmg-co-a ref.b.11111/rm/ma
AR034142A1 (es) Una composicion farmaceutica, metodo para fabricar un medicamento en base a dicha composicion y uso de la composicion
EP0799618A3 (en) Use of alpha1-adrenoreceptor antagonists in the manufacture of a medicament for the prevention and teatment of cancer
CA2361081A1 (en) Chaperonin 10 and .beta.-interferon therapy of multiple sclerosis
DE69209916T2 (de) Oral anzuwendende Arzneimittel Dapiprazol enthaltend
YU25202A (sh) Supstituisani piroli kao antiproliferativna sredstva za lečenje kancera
CO5160246A1 (es) Metodo para la prevencion o reduccion de episodios cardiovasculares asociados con intervenciones coronarias
KR950700063A (ko) 외상후 스트레스 치료제로서의 브로파로민(Brofaromine as an agent for treating post-traumatic stress)

Legal Events

Date Code Title Description
FA Abandonment or withdrawal